Search

Your search keyword '"Diletta Cavallero"' showing total 9 results
Start Over Author "Diletta Cavallero"
9 results on '"Diletta Cavallero"'

1. NAVIGATOR: an Italian regional imaging biobank to promote precision medicine for oncologic patients

Author

Rita Borgheresi, Andrea Barucci, Sara Colantonio, Gayane Aghakhanyan, Massimiliano Assante, Elena Bertelli, Emanuele Carlini, Roberto Carpi, Claudia Caudai, Diletta Cavallero, Dania Cioni, Roberto Cirillo, Valentina Colcelli, Andrea Dell’Amico, Domnico Di Gangi, Paola Anna Erba, Lorenzo Faggioni, Zeno Falaschi, Michela Gabelloni, Rosa Gini, Lucio Lelii, Pietro Liò, Antonio Lorito, Silvia Lucarini, Paolo Manghi, Francesco Mangiacrapa, Chiara Marzi, Maria Antonietta Mazzei, Laura Mercatelli, Antonella Mirabile, Francesco Mungai, Vittorio Miele, Maristella Olmastroni, Pasquale Pagano, Fabiola Paiar, Giancarlo Panichi, Maria Antonietta Pascali, Filippo Pasquinelli, Jorge Eduardo Shortrede, Lorenzo Tumminello, Luca Volterrani, Emanuele Neri, and on behalf of the NAVIGATOR Consortium Group

Subjects
Artificial intelligence, Biobanks, Biomarkers, Precision medicine, Radiomics, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Abstract NAVIGATOR is an Italian regional project boosting precision medicine in oncology with the aim of making it more predictive, preventive, and personalised by advancing translational research based on quantitative imaging and integrative omics analyses. The project’s goal is to develop an open imaging biobank for the collection and preservation of a large amount of standardised imaging multimodal datasets, including computed tomography, magnetic resonance imaging, and positron emission tomography data, together with the corresponding patient-related and omics-related relevant information extracted from regional healthcare services using an adapted privacy-preserving model. The project is based on an open-source imaging biobank and an open-science oriented virtual research environment (VRE). Available integrative omics and multi-imaging data of three use cases (prostate cancer, rectal cancer, and gastric cancer) will be collected. All data confined in NAVIGATOR (i.e., standard and novel imaging biomarkers, non-imaging data, health agency data) will be used to create a digital patient model, to support the reliable prediction of the disease phenotype and risk stratification. The VRE that relies on a well-established infrastructure, called D4Science.org, will further provide a multiset infrastructure for processing the integrative omics data, extracting specific radiomic signatures, and for identification and testing of novel imaging biomarkers through big data analytics and artificial intelligence.

Published
2022
Full Text
View/download PDF

2. Usefulness of MRI-based radiomic features for distinguishing Warthin tumor from pleomorphic adenoma: performance assessment using T2-weighted and post-contrast T1-weighted MR images

Author

Lorenzo Faggioni, Michela Gabelloni, Fabrizio De Vietro, Jessica Frey, Vincenzo Mendola, Diletta Cavallero, Rita Borgheresi, Lorenzo Tumminello, Jorge Shortrede, Riccardo Morganti, Veronica Seccia, Francesca Coppola, Dania Cioni, and Emanuele Neri

Subjects
Warthin tumor, Pleomorphic adenoma, Head and neck cancer, Parotid neoplasm, Radiomics, Magnetic resonance imaging, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Purpose: Differentiating Warthin tumor (WT) from pleomorphic adenoma (PA) is of primary importance due to differences in patient management, treatment and outcome. We sought to evaluate the performance of MRI-based radiomic features in discriminating PA from WT in the preoperative setting. Methods: We retrospectively evaluated 81 parotid gland lesions (48 PA and 33 WT) on T2-weighted (T2w) images and 52 of them on post-contrast fat-suppressed T1-weighted (pcfsT1w) images. All MRI examinations were carried out on a 1.5-Tesla MRI scanner, and images were segmented manually using the software ITK-SNAP (www.itk-snap.org). Results: The most discriminative feature on pcfsT1w images was GLCM_InverseVariance, yielding area under the curve (AUC), sensitivity and specificity of 0.9, 86 % and 87 %, respectively. Skewness was the feature extracted from T2w images with the highest specificity (88 %) in discriminating WT from PA. Conclusion: Radiomic analysis could be an important tool to improve diagnostic accuracy in differentiating PA from WT.

Published
2022
Full Text
View/download PDF

3. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

Author

Valentina Massa, Andrea Sbrana, Fortunato Ciardiello, Carminia Maria Della Corte, Floriana Morgillo, Dario Trapani, Sandro Pignata, Antonio Avallone, Vincenzo Montesarchio, Marco Messina, Paolo Antonio Ascierto, Ester Simeone, Antonio Maria Grimaldi, Marcello Curvietto, Lucia Festino, Michela Lia, Giacomo Cartenì, Luisa Piccin, Bruno Daniele, Sabino De Placido, Cesare Gridelli, Stefano Pepe, Vito Vanella, Giuseppe Palmieri, Maria Grazia Vitale, Alessandro Morabito, Margaret Ottaviano, Pasquale Rescigno, Marianna Tortora, Giovannella Palmieri, Michele Aieta, Pasquale Assalone, Laura Attademo, Francesco Bloise, Davide Bosso, Valentina Borzillo, Giuseppe Buono, Giuseppe Calderoni, Francesca Caputo, Diletta Cavallero, Alessia Cavo, Raffaele Conca, Vincenza Conteduca, Stefano De Falco, Marco De Felice, Michelino De Laurentiis, Pietro De Placido, Irene De Santo, Alfonso De Stefano, Rossella Di Franco, Vincenzo Di Lauro, Antonietta Fabbrocini, Piera Federico, Pasqualina Giordano, Mario Giuliano, Antonella Lucia Marretta, Alessia Mennitto, Sara Merler, Valeria Merz, Carlo Messina, Monica Milano, Alessandro Marco Minisini, Brigitta Mucci, Lucia Nappi, Fabiana Napolitano, Immacolata Paciolla, Martina Pagliuca, Sara Parola, Angelica Petrillo, Francovito Piantedosi, Fernanda Picozzi, Erica Pietroluongo, Veronica Prati, Vittorio Riccio, Mario Rosanova, Alice Rossi, Anna Russo, Massimiliano Salati, Giuseppe Santabarbara, Antonia Silvestri, Massimiliano Spada, Paolo Tarantino, Paola Taveggia, Federica Tomei, Tortora Vincenzo, Claudia Trojanello, Sabrina Vari, Jole Ventriglia, Fabiana Vitiello, Caterina Vivaldi, Claudia von Arx, Francesca Zacchi, Ilaria Zampiva, and Andrea Zivi

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2–positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher’s exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options.Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2–positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients’ planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.

Published
2020
Full Text
View/download PDF

5. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients

Author

Lucrezia Diodati, Stefania Crucitta, Barbara Salvadori, Beatrice Fratini, Giulia Lorenzini, Paola Cinacchi, Andrea Fontana, Marzia Del Re, Irene Bargagna, Federico Cucchiara, Diletta Cavallero, Matteo Ghilli, Claudia De Angelis, Manuela Roncella, and Romano Danesi

Subjects
0301 basic medicine, Oncology, Adult, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, medicine.medical_treatment, Antineoplastic Agents, Breast Neoplasms, Pilot Projects, medicine.disease_cause, PI3K, 03 medical and health sciences, CDK4/6 inhibitors, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, Advanced breast cancer, Liquid biopsy, Personalized medicine, Humans, neoplasms, PI3K/AKT/mTOR pathway, Retrospective Studies, Pharmacology, Mutation, Kinase, business.industry, Liquid Biopsy, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Middle Aged, medicine.disease, Metastatic breast cancer, Progression-Free Survival, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, Hormone therapy, business
Abstract

Background PI3K pathway hyperactivation due to PIK3CA mutations contributes to endocrine resistance, and PIK3CA is one of the most frequently mutated genes in breast cancer (BC), occurring approximately 40 % of HR+, HER2- advanced BC (ABC). Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have changed the treatment landscape of HR+, HER2- ABC. Putative mechanisms of resistance to CDK4/6i have been identified, but limited data are available on PI3K deregulation. The present study evaluates the impact of PIK3CA mutations on CDK4/6i plus hormone therapy and evaluates potential characteristics that may suggest for a PI3K screening in patients with ABC. Methods ABC patients were enrolled, and 12 mL of blood were collected in EDTA tubes at baseline prior to CDK4/6i plus hormone therapy. Plasma was separated and circulating free DNA (cfDNA) was extracted. PIK3CA mutation analysis was performed on a ddPCR. Selected and analyzed mutations included: p.C420R, p.E542 K, p.E545A, p.E545D, p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y. Statistical analysis were performed to investigate the predictive power of such mutations and any association with clinical factors. Results Thirty patients were enrolled. PIK3CA mutation status at baseline was independently associated with shorter median PFS (7.44 vs 12.9 months, p = 0.01) in subject receiving CDK4/6i plus hormone therapy. PIK3CA mutations were found to be associated to Ki67 expression in primary lesions (p = 0.006). Moreover, the probability to find a PI3K mutation improved considering also the therapeutic management in previous lines of treatment (McFadden's R2 = 0.415, p = 0.004; AUC of the ROC curve = 0.914). Conclusion The findings of this pilot study suggest that the presence of a PI3K mutation in liquid biopsy correlates with a worse PFS in patients with ABC receiving CDK4/6i, and that liquid biopsy is a useful tool to suggests a better tailored pharmacological intervention.

Published
2020

6. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists

Author

Sara Parola, Diletta Cavallero, Pietro De Placido, Rossella Di Franco, Francesca Zacchi, Giacomo Cartenì, Sabino De Placido, Claudia von Arx, Alice Rossi, Fernanda Picozzi, Pasquale Rescigno, Laura Attademo, Giovannella Palmieri, Carminia Maria Della Corte, Fabiana Vitiello, Anna Russo, Lucia Nappi, Michele Aieta, Alessia Mennitto, Fabiana Napolitano, Marco Messina, Giuseppe Buono, Valeria Merz, Marco De Felice, Stefano De Falco, Immacolata Paciolla, Irene De Santo, Dario Trapani, Antonio M. Grimaldi, Paolo Tarantino, Alessandro Morabito, Tortora Vincenzo, Stefano Pepe, Giuseppe Palmieri, Antonietta Fabbrocini, Diana Giannarelli, Alfonso De Stefano, Sabrina Vari, Cesare Gridelli, Vittorio Riccio, Angelica Petrillo, Martina Pagliuca, Giuseppe Calderoni, Margaret Ottaviano, Vincenza Conteduca, Michela Lia, Giuseppe Santabarbara, Ester Simeone, Valentina Borzillo, Francesca Caputo, Mario Rosanova, Marcello Curvietto, Pasquale Assalone, Brigitta Mucci, Raffaele Conca, Vito Vanella, Francovito Piantedosi, Vincenzo Montesarchio, Erica Pietroluongo, Lucia Festino, Federica Tomei, Vincenzo Di Lauro, Bruno Daniele, Caterina Vivaldi, Andrea Zivi, Veronica Prati, Pasqualina Giordano, Luisa Piccin, Francesco Bloise, Massimiliano Spada, Jole Ventriglia, Davide Bosso, Alessandro Marco Minisini, Massimiliano Salati, Monica Milano, Carlo Messina, Valentina Massa, Mario Giuliano, Claudia Trojanello, Antonella Lucia Marretta, Fortunato Ciardiello, Antonio Avallone, Marianna Tortora, Ilaria Zampiva, Alessia Cavo, Floriana Morgillo, Andrea Sbrana, Piera Federico, Maria Grazia Vitale, Sandro Pignata, Antonia Silvestri, Paola Taveggia, Sara Merler, Paolo A. Ascierto, Michelino De Laurentiis, Ottaviano, Margaret, Curvietto, Marcello, Rescigno, Pasquale, Tortora, Marianna, Palmieri, Giovannella, Giannarelli, Diana, Aieta, Michele, Assalone, Pasquale, Attademo, Laura, Avallone, Antonio, Bloise, Francesco, Bosso, Davide, Borzillo, Valentina, Buono, Giuseppe, Calderoni, Giuseppe, Caputo, Francesca, Cartenì, Giacomo, Cavallero, Diletta, Cavo, Alessia, Ciardiello, Fortunato, Conca, Raffaele, Conteduca, Vincenza, De Falco, Stefano, De Felice, Marco, De Laurentiis, Michelino, De Placido, Pietro, De Placido, Sabino, De Santo, Irene, De Stefano, Alfonso, Della Corte, Carminia Maria, Di Franco, Rossella, Di Lauro, Vincenzo, Fabbrocini, Antonietta, Federico, Piera, Festino, Lucia, Giordano, Pasqualina, Giuliano, Mario, Gridelli, Cesare, Grimaldi, Antonio Maria, Lia, Michela, Marretta, Antonella Lucia, Massa, Valentina, Mennitto, Alessia, Merler, Sara, Merz, Valeria, Messina, Carlo, Messina, Marco, Milano, Monica, Minisini, Alessandro Marco, Montesarchio, Vincenzo, Morabito, Alessandro, Morgillo, Floriana, Mucci, Brigitta, Nappi, Lucia, Napolitano, Fabiana, Paciolla, Immacolata, Pagliuca, Martina, Palmieri, Giuseppe, Parola, Sara, Pepe, Stefano, Petrillo, Angelica, Piantedosi, Francovito, Piccin, Luisa, Picozzi, Fernanda, Pietroluongo, Erica, Pignata, Sandro, Prati, Veronica, Riccio, Vittorio, Rosanova, Mario, Rossi, Alice, Russo, Anna, Salati, Massimiliano, Santabarbara, Giuseppe, Sbrana, Andrea, Simeone, Ester, Silvestri, Antonia, Spada, Massimiliano, Tarantino, Paolo, Taveggia, Paola, Tomei, Federica, Vincenzo, Tortora, Trapani, Dario, Trojanello, Claudia, Vanella, Vito, Vari, Sabrina, Ventriglia, Jole, Vitale, Maria Grazia, Vitiello, Fabiana, Vivaldi, Caterina, von Arx, Claudia, Zacchi, Francesca, Zampiva, Ilaria, Zivi, Andrea, Daniele, Bruno, Ascierto, Paolo Antonio, Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., and Ascierto, P. A.

Subjects
Male, Cancer Research, Immune checkpoint inhibitors, Programmed Cell Death 1 Receptor, Practice Patterns, Medical Oncology, B7-H1 Antigen, Antineoplastic Agents, Immunological, 0302 clinical medicine, Drug Prescription, Neoplasms, Surveys and Questionnaires, Pandemic, Prevalence, Surveys and Questionnaire, Infection control, Immunology and Allergy, CTLA-4 Antigen, 030212 general & internal medicine, Viral, Practice Patterns, Physicians', RC254-282, Clinical/Translational Cancer Immunotherapy, Oncologists, Geography, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, antineoplastic protocols, Immunological, Oncology, Italy, 030220 oncology & carcinogenesis, Molecular Medicine, Female, immunotherapy, Coronavirus Infections, Human, healthcare economics and organizations, Adult, Telemedicine, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Immunology, Antineoplastic Agents, lung neoplasms, Drug Prescriptions, Time-to-Treatment, 03 medical and health sciences, Betacoronavirus, medicine, melanoma, COVID-19, Humans, Infection Control, Pandemics, SARS-CoV-2, Medical prescription, Pharmacology, Physicians', Betacoronaviru, Coronavirus Infection, Cancer, Outbreak, Pneumonia, medicine.disease, lung neoplasm, antineoplastic protocol, Family medicine, healthcare economics and organization, Oncologist, Neoplasm
Abstract

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.MethodsThis survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2–positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher’s exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options.ResultsThis is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2–positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients’ planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.ConclusionOur study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.

Published
2020

7. 1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients

Author

Federico Cucchiara, Lucrezia Diodati, C. De Angelis, Stefania Crucitta, M. Del Re, Diletta Cavallero, G. Lorenzini, B. Fratini, Barbara Salvadori, Paola Cinacchi, Romano Danesi, I. Bargagna, and Annalisa Fontana

Subjects
Oncology, Expression (architecture), business.industry, Cancer research, Medicine, Hematology, business, medicine.disease, Metastatic breast cancer
Published
2020
Full Text
View/download PDF

8. Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer

Author

Romano Danesi, A. Falcone, C. De Angelis, Riccardo Morganti, Stefania Crucitta, I. Bertolini, Lucrezia Diodati, Eleonora Rofi, Diletta Cavallero, M. Del Re, Annalisa Fontana, and Barbara Salvadori

Subjects
0301 basic medicine, business.industry, Plasma derived, Hematology, medicine.disease, Microvesicles, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Oncology, 030220 oncology & carcinogenesis, Cancer research, Medicine, Cyclin-dependent kinase 9, business
Published
2018
Full Text
View/download PDF

9. Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer

Author

Stefania Crucitta, Riccardo Morganti, Andrea Fontana, Barbara Salvadori, Diletta Cavallero, Eleonora Rofi, I. Bertolini, Alfredo Falcone, Romano Danesi, Lucrezia Diodati, Marzia Del Re, and Claudia De Angelis

Subjects
Cancer Research, Plasma derived, Kinase, business.industry, Cancer, medicine.disease, Microvesicles, Correlation, Breast cancer, Oncology, Hormone receptor, Cancer research, medicine, In patient, business, neoplasms
Abstract

12037Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve PFS in patients with hormone receptor positive (HR+) advanced breast cancer (1). In order to better characterize the respon...

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results